SOURCE-LINKED STUDY SUMMARY
Comparative effects of central and peripheral PDE10A inhibition on weight gain following semaglutide cessation in diet-induced obese mice
Abstract summarizedQuality not appraised
- What was studied
- Whether PDE10A inhibitors could limit weight gain, including after stopping semaglutide.
- Who / model studied
- Male mice with diet-induced obesity, in a 21-day dose-response experiment and a 40-day weight-maintenance experiment. The abstract does not state sample sizes.
- Studied dose & schedule
- Dose and schedule were not reported in the source used for this summary.
- What the study found
- Mardepodect suppressed food intake and weight gain, with results described as comparable to continued semaglutide. BEN-8744 limited gain in the dose-response experiment, but after semaglutide its advantage over vehicle was not statistically clear; glucose tolerance and insulin also did not clearly improve.
- Limitations & context
- These mouse experiments do not establish weight-maintenance benefits in humans. The abstract does not report adverse-event results.
Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.64898/2026.09.07.749896